How to Read Your IMNM Muscle Biopsy Pathology Report
At a Glance
An IMNM muscle biopsy can show necrosis, muscle-fiber regeneration, MAC/C5b-9 deposits, or p62 buildup, but no finding proves the diagnosis alone. Doctors combine the report with weakness, creatine kinase levels, and anti-HMGCR or anti-SRP antibody results.
When you receive a muscle biopsy report for suspected Immune-Mediated Necrotizing Myopathy (IMNM), it can be filled with intimidating medical jargon. In simple terms, your report is looking for specific tissue patterns—such as “necrosis” (muscle cell damage), “MAC” or “C5b-9” (immune system proteins), and “p62” (a marker of cellular stress). While these findings do not confirm a diagnosis on their own, they provide important clues that can support an IMNM diagnosis when combined with your symptoms and blood tests [1][2].
What a Biopsy Can—and Cannot—Tell You
- It provides a snapshot: A biopsy shows what is happening in one small piece of muscle at one specific time.
- It is not a standalone test: No single biopsy finding is unique to IMNM [1]. Similar patterns can be seen in toxic or drug-related muscle injuries, muscular dystrophies, or severe infections [1][3].
- It requires context: Your doctor will interpret the biopsy alongside your creatine kinase (CK) blood levels, your physical weakness, and the presence of specific IMNM autoantibodies in your blood, such as anti-HMGCR or anti-SRP [1].
Breaking Down Key Terms on Your Report
Here is a plain-language breakdown of three common terms that may appear on an IMNM biopsy report:
1. Necrosis (Muscle Damage) and Regeneration
When a pathology report mentions “necrosis” or “necrotizing fibers,” it means that some of your muscle cells are actively damaged and dying [1]. This is the central biopsy finding in IMNM; in fact, “necrotizing” is right there in the disease’s name [1][4].
Your report will likely also mention “regeneration.” This indicates that your body is attempting a repair response to fix the damaged muscle fibers [1]. While seeing regeneration means your body is responding to the injury, it does not guarantee how much strength will return. Your doctor will track your functional recovery through physical exams and CK blood tests rather than relying solely on the biopsy.
In IMNM, this heavy damage and repair happens with relatively little general inflammation [1]. Specifically, pathologists look for a lack of lymphocytes (a type of white blood cell) invading healthy muscle [1][5]. You may see mentions of “macrophages” on your report—these are cleanup cells clearing dead tissue, which is expected [1]. This specific combination—high necrosis with low lymphocytic inflammation—helps narrow down the possibilities and points doctors toward IMNM [1][5].
2. MAC or C5b-9 (Complement Proteins)
“MAC” stands for Membrane Attack Complex, and it is also referred to as C5b-9 [5]. These are specialized immune system proteins called “complement.” You can think of MAC as a tool the immune system uses that can punch holes in the outer membrane of cells [6].
When pathologists see MAC (or C5b-9) deposited on your muscle cells, it can support the theory that your muscle damage is being driven by an immune system process [1]. However, MAC is not specific to IMNM and can be seen in other inflammatory muscle diseases [1]. Furthermore, its presence is highly variable in IMNM; it is found more frequently in people with the anti-HMGCR antibody than the anti-SRP antibody, but it is often absent entirely [1][6]. Because of this, if your report says MAC or C5b-9 is negative, you could still have IMNM.
3. p62 (Cellular Stress Marker)
“p62” (also called SQSTM1) is a protein involved in a cellular cleanup process called autophagy [3][7]. When muscle fibers are under severe stress or injury, their protein-handling pathways can become altered, causing p62 to build up inside the muscle cells [3][7].
Pathologists can use special stains to see this buildup. A diffuse pattern of p62 is sometimes used to support an IMNM diagnosis [3][7]. However, p62 is a general marker of muscle stress, not a standalone diagnostic test [8][9]. It is seen in many other muscle diseases, and it may not even be routinely tested in all biopsy labs. A negative or unavailable p62 stain does not rule out IMNM.
Putting the Pieces Together
Reading a pathology report can be overwhelming, but remember that the findings are just one piece of the puzzle [1][2]. Your medical team will combine these biopsy clues with your antibody status (anti-HMGCR, anti-SRP, or antibody-negative), your clinical symptoms, and your CK blood tests to confirm your diagnosis [1]. This comprehensive approach helps them choose the most appropriate treatment and monitoring plan to manage the disease.
Common questions in this guide
Can an IMNM muscle biopsy confirm the diagnosis by itself?
What does necrosis mean on my IMNM pathology report?
Does a negative MAC or C5b-9 stain rule out IMNM?
What does p62 mean on an IMNM muscle biopsy report?
How do blood tests and symptoms change the meaning of my biopsy?
Which IMNM symptoms require urgent contact with my doctor?
Related questions
Show more
Get notified when new evidence is published on Immune-mediated necrotizing myopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G, Antonini G, Garibaldi M
Autoimmunity reviews 2022; (21(2)):102993 doi:10.1016/j.autrev.2021.102993.
PMID: 34798316 - 2
Immune-Mediated Necrotizing Myopathy: Evolving Insights, Current Understanding, and Future Directions for Myopathologic Diagnosis.
Lee CM, Ferris SP
Archives of pathology & laboratory medicine 2026;.
PMID: 42307558 - 3
Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies.
Fischer N, Preuße C, Radke J, et al.
Brain pathology (Zurich, Switzerland) 2020; (30(2)):261-271 doi:10.1111/bpa.12772.
PMID: 31376301 - 4
Immune Mediated Necrotizing Myopathy: Where do we Stand?
Mohammed AGA, Gcelu A, Moosajee F, et al.
Current rheumatology reviews 2019; (15(1)):23-26 doi:10.2174/1573397114666180406101850.
PMID: 29623846 - 5
Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement.
Allenbach Y, Arouche-Delaperche L, Preusse C, et al.
Neurology 2018; (90(6)):e507-e517 doi:10.1212/WNL.0000000000004923.
PMID: 29330311 - 6
Immunopathological Characterization of Muscle Biopsy Samples from Immune-Mediated Necrotizing Myopathy Patients.
Wang Q, Li Y, Ji S, et al.
Medical science monitor : international medical journal of experimental and clinical research 2018; (24()):2189-2196 doi:10.12659/msm.907380.
PMID: 29649184 - 7
Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.
Uruha A, Goebel HH, Stenzel W
Current rheumatology reports 2021; (23(7)):56 doi:10.1007/s11926-021-01017-7.
PMID: 34212266 - 8
Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy.
Girolamo F, Lia A, Annese T, et al.
Muscle & nerve 2019; (60(3)):315-327 doi:10.1002/mus.26608.
PMID: 31172530 - 9
Autophagy in non-immune-mediated rhabdomyolysis: Assessment of p62 immunohistochemistry.
Acosta IJ, Stenzel W, Hofer M, Brady S
Muscle & nerve 2023; (67(1)):73-77 doi:10.1002/mus.27739.
PMID: 36221900
This page is for informational purposes only and does not constitute medical advice. Your pathologist or treating clinician should interpret your IMNM biopsy report and guide your care.